Class IIOngoing

fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride recall

FDA recall D-0508-2026 · initiated Apr 1, 2026

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

cGMP deviations.

Details

Product: fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDC 73702-202-15.
Recalling company: Wells Pharma of Houston LLC
Classification: Class II
Status: Ongoing
Type: Voluntary: Firm initiated
Distribution: U.S. Nationwide.
Initiated: Apr 1, 2026
FDA report date: May 6, 2026

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Source: openFDA Drug Enforcement record D-0508-2026 ↗

← All drug recalls